DX600 (trifluoroacetate salt) |
| رقم الكتالوجGC49566 |
A peptide inhibitor of ACE2
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DX600 is a potent and selective peptide inhibitor of angiotensin-converting enzyme 2 (ACE2; Kis = 2.8, 200, and 1,200 nM for recombinant, human, and murine ACE2, respectively).1,2 ACE2 is an enzyme that is cardioprotective and renoprotective.3 Inhibition of ACE2 with DX600 reduces in vitro vascular repair by CD34+ stem/progenitor cells and exacerbates myocardial injury and dysfunction in vivo.4,5
1.Huang, L., Sexton, D.J., Skogerson, K., et al.Novel peptide inhibitors of angiotensin-converting enzyme 2J. Biol. Chem.278(18)15532-15540(2003) 2.Joshi, S., Balasubramanian, N., Vasam, G., et al.Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cellsEur. J. Pharmacol.77425-33(2016) 3.Prada, J.A.H., Ferreira, A.J., Katovich, M.J., et al.Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agentsHypertension511312-1317(2008) 4.Singh, N., Joshi, S., Guo, L., et al.ACE2/Ang-(1-7)/Mas axis stimulates vascular repair-relevant functions of CD34+ cellsAm. J. Physiol. Heart. Circ. Physiol.309H1697-H1707(2015) 5.Song, B., Zhang, Z.-Z., Zhong, J.-C., et al.Loss of angiotensin-converting enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling pathwayCirc. J.77(12)2997-3006(2013)
| Cas No. | N/A | SDF | |
| Canonical SMILES | NC(CNC(CNC(CNC([C@H](CCC(O)=O)NC([C@@H]1CCCN1C([C@@H](NC([C@@H]2CCCN2C([C@@H](NC([C@@]([C@@H](C)O)([H])NC([C@@H](NC([C@H](CCCCN)NC([C@@H](NC([C@@H](NC([C@@H]3CCCN3C([C@@H](NC([C@@H](NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@@H]4CCCN4C([C@H](CO)NC([C@@H](NC([C@@H](NC([C@H](CO)NC([C@@H](NC([C@@H](NC(CNC(C)=O)=O)CC(O)=O)=O)CC5=CC=C(O)C=C5)=O)=O)CC6=CN=CN6)=O)CS)=O)=O)=O)=O)=O)CC7=CC=C(O)C=C7)=O)CC8=CC=C(O)C=C8)=O)=O)CC9=CNC%10=C9C=CC=C%10)=O)CC%11=CNC%12=C%11C=CC=C%12)=O)=O)CS)=O)=O)CC%13=CC=C(O)C=C%13)=O)=O)CC(O)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O | ||
| Formula | C141H187N35O40S2 • XCF3COOH | M.Wt | 3076.4 |
| الذوبان | DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:6): 0.13 mg/ml,Ethanol: slightly soluble | Storage | -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.3251 mL | 1.6253 mL | 3.2506 mL |
| 5 mM | 0.065 mL | 0.3251 mL | 0.6501 mL |
| 10 mM | 0.0325 mL | 0.1625 mL | 0.3251 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *